Amy Noel Melsaether MD, Presenter: Nothing to Disclose

Akshat C. Pujara MD, Abstract Co-Author: Nothing to Disclose

Roy A. Raad MD, Abstract Co-Author: Nothing to Disclose

Julia Roberts, Abstract Co-Author: Nothing to Disclose

Linda Moy MD, Abstract Co-Author: Nothing to Disclose

18FDG-PET/MRI is a new imaging modality that fuses the functional information of PET with the high soft tissue contrast of MRI at a lower radiation dose than that of PET/CT. At our own institution and others, 18FDG-PET/MRI has been validated with respect to 18FDG-PET/CT and compared to 18FDG-PET/CT in terms of lesion detection in several organ systems.  The aim of thisexhibit is to draw on our own PET/MRI experience and extensive database to 1) familiarize radiologists with how to perform 18FDG-PET/MRI, 2) demonstrate how 18FDG-PET/MRI compares with 18FDG-PET/CT in terms of organ-specific lesion detection and 3) illustrate the imaging appearances of metastases on 18FDG-PET/MRI in order to help radiologists effectively incorporate 18FDG-PET/MRI into clinical practice.  

1. Overview of how to perform 18FDG-PET/MRI including optimal indication-specific MRI sequences 2. Case-based review of our own and other published and in-press literature addressing multi-organ system lesion detection with 18FDG-PET/MRI as compared with 18FDG-PET/CT in oncologic patients 3. Case-based illustrations demonstrating sequence-specific appearances of metastases on 18FDG-PET/MRI with particular focus on common sites including bone, liver, lung, lymph nodes and brain  

http://abstract.rsna.org/uploads/2014/14008726/14008726_c66f.pdf

Melsaether, A, Pujara, A, Raad, R, Roberts, J, Moy, L, 18FDG-PET/MRI: Tutorial on Performance and Interpretation in Oncologic Patients.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14008726.html